Quantcast
Home > Quotes > EYEGW

Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) Quote & Summary Data

EYEGW 
$0.077
*  
unch
unch
Get EYEGW Alerts
*Delayed - data as of Sep. 24, 2018  -  Find a broker to begin trading EYEGW now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
N/A / N/A
Share Volume
0
50 Day Avg. Daily Volume
N/A
Previous Close
$ 0.077
52 Week High / Low
$ 0.21 / $ 0.0222
Market Cap
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
0
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $0.077 is 246.85% Higher than the 52 week low.

Intraday Last 52 Weeks
High: N/A $ 0.21
 Low: N/A $ 0.0222

Company Description (as filed with the SEC)

We are a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. We accomplish this by leveraging our two proprietary platform technologies, crosslinked thiolated carboxymethyl hyaluronic acid ("CMHA-S") and our iontophoresis drug delivery system. We are developing products using CMHA-S, a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing properties when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. Our first CMHA-S-based product, the EyeGate Ocular Bandage Gel ("OBG"), has completed a pilot trial where we announced positive top-line data.  ... More ...  

Nasdaq Official Price

Open Price:
N/A
Open Date:
N/A
Close Price:
N/A
Close Date:
N/A

Research Brokers before you trade

Want to trade FX?

Analyst Info